Anondita Medicare Limited raises Rs 91.03 crore as capacity hits 869m
Key highlights
- Anondita Medicare completed a Rs 91.03 crore rights issue at Rs 950 per share.
- Anondita Medicare added 307 million male-condom pieces of capacity in February 2026, reaching 869 million pieces annually.
- Anondita Medicare reported FY26 utilized capacity of 432.13 million pieces and utilization of 80.67%.
- Anondita Medicare listed 3 distribution partners in Nepal, 1 in Bhutan and 2 in Bangladesh.
powered by IRIS

Anondita Medicare Limited completed a Rs 91.03 crore rights issue after adding 307 million male-condom pieces in February 2026, taking installed capacity to 869 million pieces annually. The company says the proceeds will support female-condom manufacturing, infrastructure, incremental working capital, and domestic and international market expansion.
Know Anondita Medicare inside out
Results, valuation, peers and who's buying, in one view.
How will Anondita Medicare use the Rs 91.03 crore rights issue proceeds?
Anondita Medicare says the Rs 91.03 crore rights issue, issued at Rs 950 per share, is intended to fund its next phase of operating scale-up rather than one specified project. Its stated uses are expansion into female latex and non-latex condoms, manufacturing infrastructure, incremental working capital, domestic and international market expansion, and institutional and export opportunities.
The completed raise follows an increase of about 307 million male-condom pieces in annual capacity in February 2026. The presentation sets out a sequence of capital raise, capacity creation, scale-up and market expansion, but it does not allocate the Rs 91.03 crore among individual uses or disclose a project-by-project spending timetable.
Working-capital funding is specifically included as the business scales. The Noida facility had 15 operational manufacturing lines, four lines under trial and four lines under work in progress, or WIP, while Anondita Medicare also reported distribution arrangements across Nepal, Bhutan and Bangladesh in October 2026.
What is Anondita Medicare's female-condom expansion plan?
Anondita Medicare is expanding manufacturing capability for female latex and non-latex condoms, a category management describes as relatively underpenetrated with institutional and global procurement potential. The presentation does not provide a female-condom capacity figure, commercial-launch date, capital allocation or sales target for this expansion.
Management estimates commercial and public-procurement demand in the global female-condom market at 700 million to 1.5 billion pieces annually. It separately puts potential annual demand at 2 billion to 5 billion pieces, a range above its stated commercial and public-procurement demand estimate.
The company also cites global institutional channels as potential sources of volume. It estimates the United Nations Population Fund, or UNFPA, procures more than 680 million male condoms and more than 6 million female condoms annually, while non-governmental organisations and social-marketing organisations distribute about 800 million to 900 million condoms a year.
Across the channels cited, Anondita Medicare puts total institutional distribution at about 1.5 billion to 2.0 billion condoms annually. The company presents the female-condom opportunity in that procurement context, but does not state that it has won an UNFPA, Global Fund or government contract.
Got a follow-up? Ask IRIS
How much male-condom capacity has Anondita Medicare added?
Anondita Medicare added 307 million pieces of male-condom capacity on February 23, 2026, taking installed annual capacity from 562 million pieces in FY25 to 869 million pieces in FY26. The addition represented an increase of about 54.6% from the prior 562 million-piece installed base, calculated from the presentation's figures.
The capacity data show installed capacity was unchanged at 562 million pieces between FY24 and FY25 before the FY26 addition. Reported utilized capacity increased from 219.95 million pieces in FY24 to 258.84 million in FY25 and 432.13 million in FY26, while reported utilization rose from 39.14% to 46.05% and then 80.67%.
The FY26 footnote says the additional 307 million pieces were added in February 2026 at 8% to 10% utilization. Separately, the Noida, Uttar Pradesh facility is described as having about 9,290 square metres of built-up area, 15 operational lines, four lines under trial and four lines under WIP.
Which markets could Anondita Medicare pursue with the added capacity?
Anondita Medicare identifies domestic and international expansion, institutional buyers and exports as demand channels for its 869 million-piece installed base. The presentation says the newly added male-condom capacity offers scope for utilization-led growth as market demand and customer orders increase, rather than presenting utilization growth as assured.
In Nepal, Anondita Medicare reported three distribution partners appointed in October 2026. SSR Traders had commenced sales of three-piece and 10-piece condom packs, while Lotus Pharmaceuticals was to distribute condoms and personal lubricants and explore Daraz e-commerce; Hitayu Holdings was listed for surgical gloves, contraceptives, nebulisers, pregnancy test kits and lubricants.
The company also reported one Bhutan arrangement with Prema Olo Pharmaceuticals & Medical Supply, focused on condoms and surgical gloves through government hospitals and clinics, subject to applicable requirements. In Bangladesh, it listed two distributors for COBRA condoms: National Marketing Company for premium condoms and surgical gloves in northern Bangladesh, and R K Corporation for economy products in eastern interior markets.
Beyond those three markets, the presentation says export presence expanded during 2025 across Brazil, South Africa, Uzbekistan, Nepal, Kenya, Cuba and the United Arab Emirates. It also says vendor registration was completed in Brazil and South Africa and that the company completed a South Africa audit, but it does not quantify revenue, orders or volumes from those markets.
Conclusion
The Rs 91.03 crore rights issue links Anondita Medicare's funding with a manufacturing base that expanded from 562 million to 869 million male-condom pieces annually in FY26. The presentation places the raise alongside female latex and non-latex condom plans, incremental working capital and export channels, while reported utilized capacity increased from 258.84 million pieces in FY25 to 432.13 million pieces in FY26.
The next items to watch are utilization of the 307 million pieces added in February 2026, progress of the four lines under trial and four lines under WIP, and execution of the stated female-condom expansion. Management also identifies first sales in Nepal, a Bhutan government-supply route subject to requirements, and two Bangladesh distributors as near-term routes for expanded market coverage.


